格隆汇9月5日丨海天瑞声(688787.SH)公布，公司本次拟使用不超过人民币80,000万元（含本数）的暂时 闲置自有资金进行现金管理，使用期限自本公司董事会审议通过之日起12个月内有效。在前述额度及决 议有效期限内，资金可以循环滚动使用。 ...

Group 1 - Tianhua New Energy (300390.SZ) experienced a 20% limit-up today, with a turnover rate of 15.67% and a transaction volume of 2.349 billion yuan [1] - The net buying from the Shenzhen Stock Connect amounted to 190 million yuan, with total net buying from various trading seats reaching 283 million yuan [1] - The top five buying trading seats included the Shenzhen Stock Connect, which contributed 2.447579 billion yuan, accounting for 10.42% of the total transaction volume [1] Group 2 - The largest buying trading seat was the Shenzhen Stock Connect, with 46.89% of the total transactions, followed by institutional trading seats [2] - The total buying amount from the top five buying and selling trading seats combined was 4.564185 billion yuan, representing 19.43% of the total transaction volume [2]

格隆汇9月5日丨真爱美家(003041.SZ)公布，公司2025年半年度利润分配方案为：以公司现有总股本 144,000,000股为基数，向全体股东每10股派4元人民币现金(含税)。本次利润分配股权登记日2025年9月 12日。除权除息日2025年9月15日。 ...

格隆汇9月5日丨灿瑞科技(688061.SH)公布，收到公司实际控制人、董事长罗立权先生《关于提议上海 灿瑞科技股份有限公司回购公司股份的函》。罗立权先生提议公司以自有资金和回购专项贷款通过上海 证券交易所交易系统以集中竞价交易方式回购公司股份，拟回购股份资金总额：不低于人民币2000万 元，不超过人民币4000万元。 ...

Core Viewpoint - ST HuLuWa (605199.SH) has received the drug registration certificate for Cefdinir capsules from the National Medical Products Administration, indicating a significant regulatory approval for the company’s product line [1] Group 1: Product Information - Cefdinir is a third-generation broad-spectrum cephalosporin antibiotic [1] - The drug is indicated for infections caused by various bacteria, including Staphylococcus, Streptococcus, and Escherichia coli, among others [1] - Specific infections treated by Cefdinir include pharyngitis, tonsillitis, acute bronchitis, pneumonia, otitis media, sinusitis, pyelonephritis, cystitis, and several skin and soft tissue infections [1]

格隆汇9月5日丨步长制药(603858.SH)公布，公司于2025年9月4日召开第五届董事会第三十一次会议， 审议通过了《关于拟注销步长（广州）医学诊断技术有限公司暨关联交易的议案》，为优化公司资源配 置，降低管理成本，公司拟注销步长（广州）医学诊断技术有限公司（称"步长医学诊断"）。 ...

格隆汇9月5日丨步长制药(603858.SH)公布，公司控股子公司步长鼎晟股东赵路拟将其持有的步长鼎晟 3.00%股权以4.2366万元转让给谢继辉，郭玉彪拟将其持有的步长鼎晟1.00%股权以1.4122万元转让给谢 继辉，蔡云飞拟将其持有的步长鼎晟1.00%股权以1.4122万元转让给何涛。公司同意放弃上述股权转让 的优先受让权。股权转让完成后，公司持有步长鼎晟94.00%股权比例。 ...

格隆汇9月5日丨步长制药(603858.SH)公布，公司拟以0元人民币受让赵路持有的公司控股子公司步长药 妆1.50%未实缴部分股权。赵路拟将其未实缴的步长药妆1.00%股权转让给谢继辉、0.50%股权转让给王 奇，上述股权转让价格均为0元；公司同意放弃上述股权转让的优先受让权。股权转让完成后，公司持 有步长药妆94.50%股权比例。 ...

Core Viewpoint - The company, Buchang Pharma (603858.SH), announced the transfer of equity stakes in Buchang Chuanfang, resulting in a reduction of its ownership to 92.5% after the transactions [1] Group 1: Equity Transfer Details - Buchang Pharma plans to transfer 0.50% of its stake in Buchang Chuanfang to He Tao for 0.6875 million RMB [1] - Zhao Lu intends to transfer a total of 3.00% of his stake in Buchang Chuanfang, with specific allocations: 1.00% to Xie Jihui for 1.375 million RMB, and 0.50% each to Xu Bao, Gao Ge Yan, Chen Mei Shou, and He Qian, each for 0.6875 million RMB [1] - The company has agreed to waive its preferential right to acquire the transferred equity [1]

格隆汇9月5日丨步长制药(603858.SH)公布，公司控股子公司上海合璞拟对其全资子公司江苏合璞进行 减资。本次减资完成后，江苏合璞的注册资本将由5,020万元减少至500万元，上海合璞仍持有江苏合璞 100%股权。 ...